Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.
(2015) In International Journal of Cancer 137(4). p.868-877- Abstract
- Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of... (More)
- Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5145478
- author
- von Stedingk, Kristoffer LU ; De Preter, Katleen ; Vandesompele, Jo ; Noguera, Rosa ; Øra, Ingrid LU ; Koster, Jan ; Versteeg, Rogier ; Påhlman, Sven LU ; Lindgren, David LU and Axelson, Håkan LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- International Journal of Cancer
- volume
- 137
- issue
- 4
- pages
- 868 - 877
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:25652004
- wos:000356428400012
- scopus:84931564578
- pmid:25652004
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.29461
- language
- English
- LU publication?
- yes
- id
- 46b0d766-549e-471d-bad7-20b4b4902be2 (old id 5145478)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25652004?dopt=Abstract
- date added to LUP
- 2016-04-01 10:23:59
- date last changed
- 2022-04-04 17:45:42
@article{46b0d766-549e-471d-bad7-20b4b4902be2,
abstract = {{Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens.}},
author = {{von Stedingk, Kristoffer and De Preter, Katleen and Vandesompele, Jo and Noguera, Rosa and Øra, Ingrid and Koster, Jan and Versteeg, Rogier and Påhlman, Sven and Lindgren, David and Axelson, Håkan}},
issn = {{0020-7136}},
language = {{eng}},
number = {{4}},
pages = {{868--877}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.}},
url = {{http://dx.doi.org/10.1002/ijc.29461}},
doi = {{10.1002/ijc.29461}},
volume = {{137}},
year = {{2015}},
}